Watch: New Cancer Drugs from Artificial Life

In 2014 artificial life was made for the first time.

Two new nucleotides were added—X and Y—to the standard four: A, G, T, C

These new nucleotides allow for the addition of unnatural amino acids to create entirely new kinds of proteins.

Now biotech company Synthorx has announced that they have developed a new cancer drug using these artificial bacteria.

Interleukin-2 has been studied for decades as an immune system-stimulating cancer therapy, but it unfortunately comes with some serious side effects and is often unpredictable.

By adding an extra unnatural amino acid to Interleukin, Synthorx created a “Synthorin” that prolongs the protein’s activity while eliminating its immune-suppressing effects.

So, it turns out that creating artificial life is more than a cool laboratory trick—it may turn out to be a great new way to create new drugs as well.

http://www.sandiegouniontribune.com/business/biotech/sd-me-synthorx-cancer-20180430-story.html

Follow us on social media for the latest updates in B2B!

Latest

US Consumer Confidence Hits 16-Month Low on Drag From Inflation
June 29, 2022
(Bloomberg) -- US consumer confidence dropped in June to the lowest in more than a year as inflation continues to dampen Americans’ economic views. The Conference Board’s index decreased to 98.7 from a downwardly Read more
Your Relevant Solution: The Key Differentiators of Relevant Industrial
June 28, 2022
  Finding answers and delivering results is what Relevant Industrial is all about. As an industrial business in a competitive market, Relevant Industrial has learned to adapt in order to grow. Jeremy Wilcox, Read more
How Sustainability and Gamification Factor into the Future of 3PL Strategies
June 28, 2022
One of the most well-known phrases in many industries is: If you’re not innovating, you’re dying. While the saying applies to a variety of industries, today, it is cozignant of the transportation Read more